EP4436620A2 - A hydrogel formulation used as vitreous substitute and production method thereof - Google Patents
A hydrogel formulation used as vitreous substitute and production method thereofInfo
- Publication number
- EP4436620A2 EP4436620A2 EP22896250.2A EP22896250A EP4436620A2 EP 4436620 A2 EP4436620 A2 EP 4436620A2 EP 22896250 A EP22896250 A EP 22896250A EP 4436620 A2 EP4436620 A2 EP 4436620A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- hydrogel formulation
- formulation according
- collagen
- hyaluronic acid
- vitreous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 238000009472 formulation Methods 0.000 title claims abstract description 59
- 239000000017 hydrogel Substances 0.000 title claims abstract description 40
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 229920001436 collagen Polymers 0.000 claims abstract description 32
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 32
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 30
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 30
- 108010035532 Collagen Proteins 0.000 claims abstract description 27
- 102000008186 Collagen Human genes 0.000 claims abstract description 27
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 15
- 239000000499 gel Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 150000000996 L-ascorbic acids Chemical class 0.000 claims description 6
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 6
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 5
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 5
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 5
- 229920002971 Heparan sulfate Polymers 0.000 claims description 5
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 5
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 5
- 229940051593 dermatan sulfate Drugs 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 claims description 3
- 239000002211 L-ascorbic acid Substances 0.000 claims description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229940067599 ascorbyl glucoside Drugs 0.000 claims description 3
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 3
- 229940047036 calcium ascorbate Drugs 0.000 claims description 3
- 239000011692 calcium ascorbate Substances 0.000 claims description 3
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 235000001055 magnesium Nutrition 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 claims description 3
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 claims description 3
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 3
- 229960005055 sodium ascorbate Drugs 0.000 claims description 3
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 claims description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 229940119168 tetrahexyldecyl ascorbate Drugs 0.000 claims description 3
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 238000009849 vacuum degassing Methods 0.000 claims description 2
- 239000007789 gas Substances 0.000 description 11
- 230000002207 retinal effect Effects 0.000 description 11
- 210000004127 vitreous body Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108010003272 Hyaluronate lyase Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- 102000001974 Hyaluronidases Human genes 0.000 description 4
- 208000002367 Retinal Perforations Diseases 0.000 description 4
- 206010038848 Retinal detachment Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 229960002773 hyaluronidase Drugs 0.000 description 4
- 230000004264 retinal detachment Effects 0.000 description 4
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 4
- 208000002177 Cataract Diseases 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- -1 alkyl diamine Chemical class 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000029233 macular holes Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 206010057430 Retinal injury Diseases 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229950011087 perflunafene Drugs 0.000 description 2
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001351 Epiretinal Membrane Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000278713 Theora Species 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- QKENRHXGDUPTEM-UHFFFAOYSA-N perfluorophenanthrene Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C3(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C3(F)C(F)(F)C(F)(F)C21F QKENRHXGDUPTEM-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920002545 silicone oil Chemical class 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/428—Vitamins, e.g. tocopherol, riboflavin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
Definitions
- the present invention relates to a hydrogel formulation developed to be used in ophthalmological applications and as a vitreous substitute, and production method of the said formulation. More specifically, the present invention relates to a hybrid hydrogel formulation comprising cross-linked hyaluronic acid and collagen complex with stable and desirable properties.
- the vitreous is a clear gelatinous gel which fills the space between the lens and the retina. It makes up about 80% of the entire volume of the eye. More than 95% by weight of the content of the vitreous body is water; but not all water is in free form. Some of them bind to proteins and glycosaminoglycans. Water is present in a form bound to glycosaminoglycans in a ratio of approximately 15-20%, which ensures the stability of the vitreous structure. Table 1 shows various molecules present in the vitreous [1].
- the vitreous appears as a structure with its own viscoelastic properties due to a high hyaluronic acid concentration.
- the collagen-glycosaminoglycan and water frame ensure the transparency of the medium, while acting as support for the vision and accommodation mechanism.
- the gelatinous structure is adjacent to the posterior hyaloid membrane (vitreous cortex) and it is more dense in the ora serrata.
- the presence of active molecules provides control over inflammation, proliferation and neovascularization by means of acting as a barrier against infection (bacterial, not viral) [2; 3].
- the vitreous monitors the processes of drug transport and release within the eye, as well as oxygen and nutrients [4J.
- vitreous substitutes Retinal tamponades
- the present invention generally relates to substances that can be used instead of clear, transparent and gelatinous vitreous humor in the vitreous cavity of the eye, behind the lens and in front of the retina, and production and usage methods thereof.
- a composition of materials comprising a hydrogel polymer that can be used in place of vitreous humor is disclosed.
- This composition comprises a) oxidated hyaluronic acid, b) a dihydrazide which crosslinks oxidated hyaluronic acid.
- the hydrogel polymer exhibits the following properties: a) transparent and colorless; and b) transforming from a liquid state into a gel-matrix at 37 C°.
- the present invention generally relates to cross-linked hyaluronic acid gels obtained by reaction of activated carboxylic groups of hyaluronic acid, of extractive or biosynthetic source, with a polyamine, particularly a linear alkyl diamine.
- the cross-linked hyaluronic acids can optionally be sulphated or functionalized with hemisuccinyl groups. Such functionalization of hyaluronic acid gels serves many areas.
- the invention relates to an ophthalmologic composition which can be used as vitreous humor.
- the vitreous humor composition is a gel (hydrogel or particle) and a therapeutic agent, wherein the therapeutic agent is an antioxidant.
- the object of the present invention is to create a composition that has the physical properties of the natural vitreous and supports methods that can be used in the treatment of ophthalmological disorders.
- EP0185070 an application known in the state of the art, the present invention relates to a method used after vitrectomy in retinal surgery in the field of ophthalmology, which relates to remove partially or completely the vitreous and replace it by injecting cross-linked hyaluronic acid gel.
- the present invention comprises compositions which are heavier than the vitreous humor and contain one or more glycosaminoglycans (GAGs) and are used in retinal injuries such as retinal detachments (for example, subretinal detachments) and macular holes.
- GAGs glycosaminoglycans
- These compounds are referred to as "tamponade compositions" for retinal repair and are stated to be useful for repairing retinal damage.
- New methods are described in the present invention, which include administering a tamponade composition into the vitreous cavity of an eye in a procedure for repairing a retinal insult, for example, an inferior retinal detachment or a macular hole.
- New tamponade compositions include i) a nontoxic liquid that is denser than aqueous humor, e.g., deuterium-containing heavy water, and ii) one or more GAGs.
- the new therapeutic methods and compositions disclosed herein have a number of advantages. Tamponade compositions are denser than aqueous humor. Therefore, awkward post-operative positioning of a subject's head is not required to repair inferior retinal tears and macular holes.
- the new compositions are effective as tamponades due to their high interfacial tension, high surface tension, and high viscosity. Their high surface tension and high interfacial tension provides the new compositions with the ability to press the retinal tissue against the inner wall of the eye, thereby keeping the tissue in place and preventing later detachment.
- the present invention relates to the use of cross-linked GAG or salts thereof cross-linked with a multifunctional epoxy compound, as a therapeutic agent, a medical device or skin cosmetics and medicine, especially for vitreous (glass-like body)
- vitreous substitutes Today, efforts to develop alternative vitreous substitutes that can be used instead of natural vitreous continue.
- Existing vitreous substitutes currently in use can be classified into three main categories: gases (air, expandable gases), liquids (balanced salt solutions, perfluorocarbon liquids, semi-fluorinated alkanes, silicone oils, etc.), and polymers (natural, semi-synthetic). These vitreous substitutes that are being used have several negative characteristics.
- PFCLs perfluorocarbon liquids
- Their intravitreal presence in rabbit eyes for more than 2-4 days most probably causes mechanical damage to the cells and it has been shown that it causes irreversible cell damage in the inferior retina 6 days after surgery as a result of almost complete emulsification [6].
- PFD perfluorodecalin
- perfluoroperhydrophenanthrene have demonstrated dysregulation in retinal cell growth pattern, neurite loss, and other toxic effects; as a result of this, it has been thought that the high specific gravity of perfluorocarbon liquids compress and disorganize the retinal structure [7; 8].
- SFAs semi-fluorinated alkanes
- Silicon Oil can pass through retinal detachments more easily than gas, under traction, with a lower surface tension than gas or salt water.
- the oil is hydrophobic and therefore it does not have the necessary retinal contact.
- SO is clear, its refractive index is 1.4, thereby requiring optical adjustments compared to the vitreous refractive index of 1.3.
- tamponade of the inferior retina is difficult.
- Emulsification has been shown to be a problem with SO, however, in a few studies, less than 5% of eyes had fat emulsification after surgery [9].
- a combination of SO and SFAs does not provide good superior and inferior tamponade at the same time. Bubble formation can be observed with the use of these products, and the bubble, as a whole, acts as a tampon heavier than water. [10].
- Biopolymers are lighter than water, limiting their use as inferior retinal tamponades. In addition, they tend to degrade rapidly in vivo.
- the biodegradation rate of experimental hyaluronan implants is related to their chemical structure and ranges from 60 to 150 days [11]. Even though hyaluronic acid has been used with limited inflammatory effect, the use of collagen has been limited to inflammation and moderate to severe ocular pain. Collagen gels break as they pass through the syringe during injection and their function as a structural gel is impaired.
- the objective of the present invention is to provide a hydrogel formulation comprising cross-linked hyaluronic acid and collagen components, developed for use in ophthalmological applications and as a vitreous substitute.
- Another objective of the present invention is to develop a hydrogel formulation which is transparent, clear, like natural vitreous, has viscoelastic properties, refractive index and density similar to natural vitreous, is non-toxic, biocompatible, can maintain its function as vitreous substitute for a long time and provides convenience in application.
- a further objective of the present invention is to develop a production method suitable for providing the formulation of the present invention.
- the present invention relates to a hydrogel formulation developed to be used in ophthalmological applications and as a vitreous substitute.
- the said hydrogel formulation has a hybrid structure; it comprises hyaluronic acid (HA) and collagen, which are contained the most in composition of the vitreous.
- HA hyaluronic acid
- hyaluronic acid and collagen components are cross-linked to each other to form the cross-linked HA- collagen complex and thus the hydrogel.
- This process takes place by the reaction between the carboxyl groups in the structure of hyaluronic acid and the amine/carboxyl groups in the structure of collagen [18].
- EDC.HC1 l-ethyl-3- carbodiimide hydrochloride
- NHS N-hydroxysuccinimide
- the hybrid and cross-linked hydrogel form of the invention will ensure that the hyaluronic acid and collagen components remain in the area where they are injected during vitreoretinal surgery for a longer period of time.
- Hyaluronic acid in the formulation of the invention is selected from the group comprising a molecular weight of 5000 Da to 5xl0 6 Da and combinations of these molecular weights.
- the formulation of the present invention comprises collagen selected from at least one of the group comprising type 1-2-3-4 collagen, hydrolyzed collagen, including animal origin, plant origin, recombinant human collagen or mixtures thereof.
- the hydrogel formulation of the invention is a hydrophilic structure with a similar refractive index, pH value, viscosity (cP) and density with natural vitreous.
- the pH value of the hydrogel formulation is in the range of 7.0 to 7.4, preferably in the range of 7.1 to 7.3.
- the density of the hydrogel formulation is in the range of 1,000 to 1.008 g/cm 3 .
- the refractive index of the hydrogel formulation is in the range of 1,3345 to 1,3348.
- the viscosity (cP) of the hydrogel formulation is in the range of 300 to 2000.
- Sulfated GAGs which are included in the formulation of the present invention and are also included in the vitreous structure as versican and IX Collagen, are usually bound to proteins as part of a proteoglycan. It is important in maintaining the structural integrity of the tissue and provides resistance to compression. It also maintains adequate spacing between collagen fibrils and can facilitate the regulation of a wide variety of biological processes, including development, angiogenesis, and blood coagulation, as well as maintaining vitreoretinal adhesion [12].
- Sulfated glycosaminoglycans in the formulation of the present invention are at least one of the group comprising chondroitin sulfate (CS), dermatan sulfate (DS), heparan sulfate (HS), heparin (Hep), or mixtures thereof.
- the ascorbic acid comprised by the formulation within the scope of the present invention is present in the vitreous body at higher concentrations than the plasma. It has an important role in the age-related liquefaction process and can inhibit neovascularization and increase the proliferation of hyalocytes. It can also prevent rebleeding by inhibiting pathological neovascularization. Recent studies have shown that the antioxidant properties of ascorbic acid can also reduce early cataract formation [13].
- Ascorbic acid derivatives in the formulation of the present invention are at least one of the group of L-ascorbic acid, tetrahexyldecyl ascorbate, ascorbyl glucoside, ethylated ascorbic acid, ascorbyl palmitate, magnesium ascorbyl palmitate, magnesium ascorbyl phosphate, calcium ascorbate, sodium ascorbate and sodium ascorbyl phosphate or mixtures thereof.
- the cross-linked gel comprising HA in the present invention is broken down by the hyaluronidase enzymes in the body over time. Inhibiting hyaluronidase enzymes means that the HA-containing gel stays where it is injected for a longer time. It is known that especially the sulfated GAGs and vitamin C derivatives, with the inhibition of hyaluronidase, increase the residence tune of the alternative vitreous substitute of the present invention in the body [15].
- sulfated GAGs which are also used in the said formulation, are good hyaluronidase inhibitors [14].
- the inhibition effect is thought to be that negatively charged sulfated GAGs interact electrostatically with the positively charged hyaluronidase enzyme and prevent the enzymes from binding to HA [15].
- vitamin C derivatives in the formulation of the present invention also play an auxiliary role in inhibiting hyaluronidase. In a study, it was reported that Vitamin C inhibits amylase enzymes [16]. In addition, in another study, it was reported that Vitamin C inhibited bovine testicular hyaluronidase [17].
- the viscoelastic formulas to be prepared in the buffer solution with disposable sterile syringes are as follows:
- They comprise linear and/or cross-linked forms of sodium hyaluronate with a molecular weight of 5000 Da - 5xl0 6 Da, and is present in the formulation in the concentration range of 0.1 mg/ml - 20 mg/ml.
- 3- Sulfated GAGs in the formulation are selected from a group comprising the following components and their combinations in the concentration range of 0.005 mg/ml - 5 mg/ml.
- Vitamin C derivatives in the formulation are selected from a group comprising the following components and their combinations in the concentration range of 0.002 mg/ml - 2 mg/ml. • L-ascorbic acid
- a preferred embodiment of the invention is the method for preparing the formulation, which comprises the following steps:
- the concentration value of hyaluronic acid in the formulation is in the range of 1 mg/ml to 20 mg/ml, preferably 1 mg/ml to 5mg/ml.
- the formulation of the present invention additionally comprises at least one pharmaceutically and ophthalmologically acceptable excipient.
- non-cross-linked components e.g. non-cross-linked hyaluronic acid
- lubricating agents to facilitate injection.
- the invention comprises at least one excipient selected from the group of mineral salts or mixtures thereof.
- HA-Col gels were washed 4 more times with ethyl alcohol and dried under vacuum at 35 °C for 2 days.
- the formulations were prepared in buffer solution in accordance with the amounts in Table 3 and filled into syringes and sterilized. Table 3.
- Examples of Formulations pH, viscosity, density and refractive index values of 5 different formulations with different HA-Collagen cross-linked hydrogel ratios were measured, and the results are summarized in Table 4.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention relates to a hydrogel formulation developed to be used in ophthalmological applications and as a vitreous substitute. More specifically, the present invention relates to a hybrid hydrogel formulation comprising cross-linked hyaluronic acid and collagen complex.
Description
DESCRIPTION
A HYDROGEL FORMULATION USED AS VITREOUS SUBSTITUTE AND PRODUCTION METHOD THEREOF
Field of the Invention
The present invention relates to a hydrogel formulation developed to be used in ophthalmological applications and as a vitreous substitute, and production method of the said formulation. More specifically, the present invention relates to a hybrid hydrogel formulation comprising cross-linked hyaluronic acid and collagen complex with stable and desirable properties.
Background of the Invention
The vitreous is a clear gelatinous gel which fills the space between the lens and the retina. It makes up about 80% of the entire volume of the eye. More than 95% by weight of the content of the vitreous body is water; but not all water is in free form. Some of them bind to proteins and glycosaminoglycans. Water is present in a form bound to glycosaminoglycans in a ratio of approximately 15-20%, which ensures the stability of the vitreous structure. Table 1 shows various molecules present in the vitreous [1].
Table 1. Biochemical composition of Vitreous
As shown in Table 2, the physical characteristics need to be well known in order to recognize its active role in ocular physiology [1]. The vitreous appears as a structure with its own viscoelastic properties due to a high hyaluronic acid concentration. The collagen-glycosaminoglycan and water frame ensure the transparency of the medium, while acting as support for the vision and accommodation mechanism. The gelatinous structure is adjacent to the posterior hyaloid membrane (vitreous cortex) and it is more dense in the ora serrata. The presence of active molecules provides control over inflammation, proliferation and neovascularization by means of acting as a barrier against infection (bacterial, not viral) [2; 3]. Lastly, the vitreous monitors the processes of drug transport and
release within the eye, as well as oxygen and nutrients [4J. These facts show that the vitreous is not only a filling agent, but it also is a physiologically active element in the eye.
Table 2. Physical Characteristics of Vitreous.
Recently, there has been significant progress in vitreoretinal surgery with the development of surgical instruments, drugs, and new surgical techniques. Numerous pathologies such as retinal detachment, diabetic retinopathy, and proliferative vitreoretinopathy require partial or complete removal of the vitreous. This situation has led to the need for vitreous substitutes (retinal tamponades). Ideal vitreous substitutes should have the following characteristics:
• It should mimic the natural vitreous
• It should be easily manipulated during surgery
• It should have viscoelastic characteristics similar to natural vitreous
• It should be transparent
• It should have a refractive index and density similar to that of natural vitreous.
• It should be biologically and chemically inert
• It should not cause toxic reactions
• It should be biocompatible
• It should be easily injectable and aspirable
• It should be able to maintain its vitreous substitute task for a minimum of 6 months
In Australian patent document no AU2011215775, an application known in the state of the art, the present invention generally relates to substances that can be used instead of clear, transparent and gelatinous vitreous humor in the vitreous cavity of the eye, behind the lens and in front of the retina, and production and usage methods thereof. In this technique, a composition of materials comprising a hydrogel polymer that can be used in place of vitreous humor is disclosed. This composition comprises a) oxidated hyaluronic acid, b) a dihydrazide which crosslinks oxidated hyaluronic acid. The hydrogel polymer exhibits the following properties: a) transparent and colorless; and b) transforming from a liquid state into a gel-matrix at 37 C°. These properties make the material disclosed in the patent useful as a vitreous humor.
In European patent document no EP1144459B2, an application known in the state of the art, the present invention generally relates to cross-linked hyaluronic acid gels obtained by reaction of activated carboxylic groups of hyaluronic acid, of extractive or biosynthetic source, with a polyamine, particularly a linear alkyl diamine. The cross-linked hyaluronic acids can optionally be sulphated or functionalized with hemisuccinyl groups. Such functionalization of hyaluronic acid gels serves many areas. They have many uses such as synovial fluid, vitreous humor, drug release in controlled release systems, vascular prostheses, biohybrid organs, ophthalmic and otological compositions, prostheses, implants and medical devices, thanks to its healing and anti-adhesion properties.
In the international patent document no WO2020163872, an application known in the state of the art, the invention relates to an ophthalmologic composition which can be used as vitreous humor. Here, the vitreous humor composition is a gel (hydrogel or particle) and a therapeutic agent, wherein the therapeutic agent is an antioxidant. The object of the present invention is to create a composition that has the physical properties of the natural vitreous and supports methods that can be used in the treatment of ophthalmological disorders.
In European patent document no EP0185070, an application known in the state of the art, the present invention relates to a method used after vitrectomy in retinal surgery in the field of ophthalmology, which relates to remove partially or completely the vitreous and replace it by injecting cross-linked hyaluronic acid gel.
In United States patent document no US20060159771, an application known in the state of the art, the present invention comprises compositions which are heavier than the vitreous humor and contain one or more glycosaminoglycans (GAGs) and are used in retinal injuries such as retinal detachments (for example, subretinal detachments) and macular holes. These compounds are referred to as "tamponade compositions" for retinal repair and are stated to be useful for repairing retinal damage. New methods are described in the present invention, which include administering a tamponade composition into the vitreous cavity of an eye in a procedure for repairing a retinal insult, for example, an inferior retinal detachment or a macular hole. New tamponade compositions include i) a nontoxic liquid that is denser than aqueous humor, e.g., deuterium-containing heavy water, and ii) one or more GAGs. The new therapeutic methods and compositions disclosed herein have a number of advantages. Tamponade compositions are denser than aqueous humor. Therefore, awkward post-operative positioning of a subject's head is not required to repair inferior retinal tears and macular holes. The new compositions are effective as tamponades due to their high interfacial tension, high surface tension, and high viscosity. Their high surface tension and high interfacial tension provides the new compositions with the ability to press the retinal tissue against the inner wall of the eye, thereby keeping the tissue in place and preventing later detachment.
In European patent document no EP0167363, an application known in the state of the art, the present invention relates to the use of cross-linked GAG or salts thereof cross-linked with a multifunctional epoxy compound, as a therapeutic
agent, a medical device or skin cosmetics and medicine, especially for vitreous (glass-like body)
Today, efforts to develop alternative vitreous substitutes that can be used instead of natural vitreous continue. Existing vitreous substitutes currently in use can be classified into three main categories: gases (air, expandable gases), liquids (balanced salt solutions, perfluorocarbon liquids, semi-fluorinated alkanes, silicone oils, etc.), and polymers (natural, semi-synthetic). These vitreous substitutes that are being used have several negative characteristics.
In gas-based substitutes, even though the expanding nature of the gas allows the endotamponade effect to be maintained, in severe cases, a sudden increase in intraocular pressure can cause central retinal artery occlusion. Similarly, patients should avoid higher altitudes to avoid dangerous gas expansion. Perfluorocarbon gas, which has a lower density than vitreous, does not effectively buffer the inferior retina [5]. Although inferior retinal tamponade is clinically achieved using expanding gas, a face-down positioning is required for several days until the inferior detachments are closed and retinal fluid is reabsorbed, which can significantly reduce patient compliance. Adverse effects include gas-induced cataract formation and corneal endothelial changes. In addition, as with air, gases have lower refractive indices compared to the cornea, anterior chamber fluid, and lens. Visual rehabilitation can take up to 1 month.
Currently, perfluorocarbon liquids (PFCLs) are mostly limited to intraoperative use over longer periods of time as a result of their toxicity. Their intravitreal presence in rabbit eyes for more than 2-4 days most probably causes mechanical damage to the cells and it has been shown that it causes irreversible cell damage in the inferior retina 6 days after surgery as a result of almost complete emulsification [6]. In vitro experiments carried out with perfluorodecalin (PFD) and perfluoroperhydrophenanthrene have demonstrated dysregulation in retinal cell growth pattern, neurite loss, and other toxic effects; as a result of this, it has
been thought that the high specific gravity of perfluorocarbon liquids compress and disorganize the retinal structure [7; 8].
Cataract formation and emulsification, together with the presence of soft epiretinal membranes and cellular material, are the main problems associated with the use of semi-fluorinated alkanes (SFAs), which are among other liquid substitutes.
Silicon Oil (SO) can pass through retinal detachments more easily than gas, under traction, with a lower surface tension than gas or salt water. The oil is hydrophobic and therefore it does not have the necessary retinal contact. Although SO is clear, its refractive index is 1.4, thereby requiring optical adjustments compared to the vitreous refractive index of 1.3. Considering the low specific gravity of SO, tamponade of the inferior retina is difficult. Emulsification has been shown to be a problem with SO, however, in a few studies, less than 5% of eyes had fat emulsification after surgery [9].
A combination of SO and SFAs does not provide good superior and inferior tamponade at the same time. Bubble formation can be observed with the use of these products, and the bubble, as a whole, acts as a tampon heavier than water. [10].
Major problems with natural and semi- synthetic polymers: Biopolymers are lighter than water, limiting their use as inferior retinal tamponades. In addition, they tend to degrade rapidly in vivo. The biodegradation rate of experimental hyaluronan implants is related to their chemical structure and ranges from 60 to 150 days [11]. Even though hyaluronic acid has been used with limited inflammatory effect, the use of collagen has been limited to inflammation and moderate to severe ocular pain. Collagen gels break as they pass through the syringe during injection and their function as a structural gel is impaired.
Summary of the Invention
The objective of the present invention is to provide a hydrogel formulation comprising cross-linked hyaluronic acid and collagen components, developed for use in ophthalmological applications and as a vitreous substitute.
Another objective of the present invention is to develop a hydrogel formulation which is transparent, clear, like natural vitreous, has viscoelastic properties, refractive index and density similar to natural vitreous, is non-toxic, biocompatible, can maintain its function as vitreous substitute for a long time and provides convenience in application.
A further objective of the present invention is to develop a production method suitable for providing the formulation of the present invention.
Detailed Description of the Invention
The present invention relates to a hydrogel formulation developed to be used in ophthalmological applications and as a vitreous substitute.
The said hydrogel formulation has a hybrid structure; it comprises hyaluronic acid (HA) and collagen, which are contained the most in composition of the vitreous.
In order to obtain a hybrid hydrogel of the present invention, hyaluronic acid and collagen components are cross-linked to each other to form the cross-linked HA- collagen complex and thus the hydrogel. This process takes place by the reaction between the carboxyl groups in the structure of hyaluronic acid and the amine/carboxyl groups in the structure of collagen [18]. During this reaction, first the carboxylic acid groups in the structure of HA are activated with l-ethyl-3- carbodiimide hydrochloride (EDC.HC1). Then, N-hydroxysuccinimide (NHS), a nucleophilic reagent, converts the activated intermediate product to the NHS ester. These groups that are formed carry out cross-linking by entering into condensation reaction with the amine/carboxyl groups in the structure of collagen.
EDC.HC1 and NHS reagents used in this process are removed during the purification of the product. Thus, the absence of any synthetic cross-linking agent makes the final product non-toxic.
While hyaluronic acid and collagen can be easily biodegraded in the free state, the hybrid and cross-linked hydrogel form of the invention will ensure that the hyaluronic acid and collagen components remain in the area where they are injected during vitreoretinal surgery for a longer period of time.
Hyaluronic acid in the formulation of the invention is selected from the group comprising a molecular weight of 5000 Da to 5xl06 Da and combinations of these molecular weights.
The formulation of the present invention comprises collagen selected from at least one of the group comprising type 1-2-3-4 collagen, hydrolyzed collagen, including animal origin, plant origin, recombinant human collagen or mixtures thereof.
The hydrogel formulation of the invention is a hydrophilic structure with a similar refractive index, pH value, viscosity (cP) and density with natural vitreous.
In the preferred embodiment of the invention, the pH value of the hydrogel formulation is in the range of 7.0 to 7.4, preferably in the range of 7.1 to 7.3.
In the preferred embodiment of the invention, the density of the hydrogel formulation is in the range of 1,000 to 1.008 g/cm3.
In the preferred embodiment of the present invention, the refractive index of the hydrogel formulation is in the range of 1,3345 to 1,3348.
In the preferred embodiment of the present invention, the viscosity (cP) of the hydrogel formulation is in the range of 300 to 2000.
Sulfated GAGs (SGAGs), which are included in the formulation of the present invention and are also included in the vitreous structure as versican and IX Collagen, are usually bound to proteins as part of a proteoglycan. It is important in maintaining the structural integrity of the tissue and provides resistance to compression. It also maintains adequate spacing between collagen fibrils and can facilitate the regulation of a wide variety of biological processes, including development, angiogenesis, and blood coagulation, as well as maintaining vitreoretinal adhesion [12]. Sulfated glycosaminoglycans in the formulation of the present invention are at least one of the group comprising chondroitin sulfate (CS), dermatan sulfate (DS), heparan sulfate (HS), heparin (Hep), or mixtures thereof.
The ascorbic acid comprised by the formulation within the scope of the present invention is present in the vitreous body at higher concentrations than the plasma. It has an important role in the age-related liquefaction process and can inhibit neovascularization and increase the proliferation of hyalocytes. It can also prevent rebleeding by inhibiting pathological neovascularization. Recent studies have shown that the antioxidant properties of ascorbic acid can also reduce early cataract formation [13]. Ascorbic acid derivatives in the formulation of the present invention are at least one of the group of L-ascorbic acid, tetrahexyldecyl ascorbate, ascorbyl glucoside, ethylated ascorbic acid, ascorbyl palmitate, magnesium ascorbyl palmitate, magnesium ascorbyl phosphate, calcium ascorbate, sodium ascorbate and sodium ascorbyl phosphate or mixtures thereof.
The cross-linked gel comprising HA in the present invention is broken down by the hyaluronidase enzymes in the body over time. Inhibiting hyaluronidase enzymes means that the HA-containing gel stays where it is injected for a longer time. It is known that especially the sulfated GAGs and vitamin C derivatives,
with the inhibition of hyaluronidase, increase the residence tune of the alternative vitreous substitute of the present invention in the body [15].
It is known that sulfated GAGs, which are also used in the said formulation, are good hyaluronidase inhibitors [14]. The inhibition effect is thought to be that negatively charged sulfated GAGs interact electrostatically with the positively charged hyaluronidase enzyme and prevent the enzymes from binding to HA [15]. It is known that vitamin C derivatives in the formulation of the present invention also play an auxiliary role in inhibiting hyaluronidase. In a study, it was reported that Vitamin C inhibits amylase enzymes [16]. In addition, in another study, it was reported that Vitamin C inhibited bovine testicular hyaluronidase [17].
In the present invention, the viscoelastic formulas to be prepared in the buffer solution with disposable sterile syringes are as follows:
1- They comprise linear and/or cross-linked forms of sodium hyaluronate with a molecular weight of 5000 Da - 5xl06 Da, and is present in the formulation in the concentration range of 0.1 mg/ml - 20 mg/ml.
2- They comprise linear and/or cross-linked forms of collagen in the formulation, and it will be present in the formulation in the concentration range of 0.0001 mg/ml - 2 mg/ml.
3- Sulfated GAGs in the formulation are selected from a group comprising the following components and their combinations in the concentration range of 0.005 mg/ml - 5 mg/ml.
• Chondroitin sulfate
• Dermatan sulfate
• Heparin
• Heparan sulfate
4- Vitamin C derivatives in the formulation are selected from a group comprising the following components and their combinations in the concentration range of 0.002 mg/ml - 2 mg/ml.
• L-ascorbic acid
• Tetrahexyldecyl ascorbate
• Ascorbyl glucoside
• Ethylated ascorbic acid
• Ascorbyl palmitate
• Magnesium ascorbyl palmitate
• Magnesium ascorbyl phosphate
• Calcium ascorbate
• Sodium ascorbate
• Sodium ascorbyl phosphate
A preferred embodiment of the invention is the method for preparing the formulation, which comprises the following steps:
- Producing hyaluronic acid-collagen hybrid cross-linked gels
- Adding non-crosslinked hyaluronic acid and collagen
- Adding sulfated GAG
- Adding vitamin C
- Mixing for 5-50 hours at a mixing speed of 10-250 rpm
- Vacuum degassing of the mixture
- Filling the mixture into syringes
- Performing vapor sterilization process
- Labelling and packaging
- Performing ethylene oxide sterilization
In an embodiment of the invention, the concentration value of hyaluronic acid in the formulation is in the range of 1 mg/ml to 20 mg/ml, preferably 1 mg/ml to 5mg/ml.
In another preferred embodiment of the invention, the formulation of the present invention additionally comprises at least one pharmaceutically and ophthalmologically acceptable excipient.
The above-mentioned non-cross-linked components (e.g. non-cross-linked hyaluronic acid) are used as lubricating agents to facilitate injection.
In the said embodiment of the invention, the invention comprises at least one excipient selected from the group of mineral salts or mixtures thereof.
The following examples are to better illustrate the subject matter of the invention and the subject matter of the invention is not limited to these examples.
Examples
Preparation of Cross-Linked Hyaluronic Acid-Collagen hydrogels
2% by weight of sodium hyaluronate (Mw: 3xl06 Da), relative to the total solution, was dissolved in deionized water. Then, 0.2% by weight of collagen was added and mixed at 40 °C for 15 minutes. Then, 0.1% by weight of a 100 mM EDC:NHS solution pre-prepared with a mole ratio of 3:1 was added and incubated at 40 °C for 3 hours and left for crosslinking reaction. The resulting gels were then washed 5 times in buffer solution (pH = 7.4) to remove unreacted impurities. 3 times by volume was then precipitated in ethyl alcohol. After precipitation, upon removal of alcohol by decanting, HA-Col gels were washed 4 more times with ethyl alcohol and dried under vacuum at 35 °C for 2 days. The formulations were prepared in buffer solution in accordance with the amounts in Table 3 and filled into syringes and sterilized.
Table 3. Examples of Formulations
pH, viscosity, density and refractive index values of 5 different formulations with different HA-Collagen cross-linked hydrogel ratios were measured, and the results are summarized in Table 4.
Table 4.
When the results in Table 4 are examined, the pH, viscosity, density and refractive index results of the formulations with different HA-Collagen cross-linked gel
ratios are similar to the results of the natural vitreous. Therefore, these formulations prepared within the scope of the present invention can be used as alternative vitreous substitutes.
REFERENCES
[1]. Donati, Simone, et al. "Vitreous substitutes: the present and the future."
BioMed research international 2014 (2014).
[2]. Kleinberg, Teri T., et al. "Vitreous substitutes: a comprehensive review."
Survey of ophthalmology 56.4 (2011): 300-323.
[3]. Los, Leonoor I., et al. "Age-related liquefaction of the human vitreous body: LM and TEM evaluation of the role of proteoglycans and collagen." Investigative ophthalmology & visual science 44.7 (2003): 2828-2833.
[4]. Filas, Benjamen A., Ying-Bo Shui, and David C. Beebe. "Computational model for oxygen transport and consumption in human vitreous." Investigative ophthalmology & visual science 54.10 (2013): 6549-6559.
[5]. Pastor, J. Carlos. "Proliferative vitreoretinopathy: an overview." Survey of ophthalmology 43.1 (1998): 3-18.
[6]. Migliavacca, Luca, Ferdinando Bottoni, and Stefano Miglior.
"Experimental short-term tolerance to perfluorodecalin in the rabbit eye: a histopathological study." Current eye research 17.8 (1998): 828-835.
[7]. Malchiodi-Albedi, Fiorella, et al. "Biocompatibility assessment of silicone oil and perfluorocarbon liquids used in retinal reattachment surgery in rat retinal cultures." Journal of Biomedical Materials Research: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials 60.4 (2002):548-555.
[8]. Matteucci, Andrea, et al. ' Biocompatibility assessment of liquid artificial vitreous replacements: relevance of in vitro studies." Survey of ophthalmology 52.3 (2007):289-299.
[9]. Azen, Stanley P., et al. "Silicone oil in the repair of complex retinal detachments: a prospective observational multicenter study." Ophthalmology 105.9 (1998): 1587-1597.
[10]. Heimann, H., T. Stappler, and D. Wong. "Heavy tamponade 1: a review of indications, use, and complications." Eye 22.10 (2008): 1342-1359.
[11]. Avitabile, Teresio, et al. "Biocompatibility and biodegradation of intravitreal hyaluronan implants in rabbits." Biomaterials 22.3 (2001): 195-200.
[12]. Buzza, Marguerite S., et al. "Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin." Journal of Biological Chemistry 280.25 (2005): 23549-23558.
[13]. Shui, Ying-Bo, et al. "The gel state of the vitreous and ascorbatedependent oxygen consumption: relationship to the etiology of nuclear cataracts." Archives of ophthalmology 127.4 (2009): 475-482.
[14]. Wolf, Robert A., et al. "Heparin inhibits bovine testicular hyaluronidase activity in myocardium of dogs with coronary artery occlusion." The American journal of cardiology 53.7 (1984): 941-944.
[15]. Girish, K. S., and K. Kemparaju. "Inhibition of Naja naja venom hyaluronidase by plant-derived bioactive components and polysaccharides." Biochemistry (Moscow)70.8(2005):948-952.
[16]. Abell, Andrew D., Maureen J. Ratcliffe, and Juliet Gerrard. "Ascorbic acid-based inhibitors of a- amylases." Bioorganic & medicinal chemistry letters 8.13 (1998): 1703-1706. [17]. Menzel, E. J., and C. Farr. "Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses." Cancer letters 131.1 (1998): 3-11.
[18]. Jia, Weibin, et al. "Fabrication and comprehensive characterization of biomimetic extracellular matrix electrospun scaffold for vascular tissue engineering applications." Journal of Materials Science 54.15 (2019): 10871-10883.
Claims
1. A hybrid hydrogel formulation comprising a cross-linked hyaluronic acid and collagen complex for use as a vitreous substitute.
2. A hydrogel formulation according to claim 1, characterized in that the molecular weight of hyaluronic acid is in the range of 5000 Da to 5xl0e Da.
3. A hydrogel formulation according to claim 2, characterized in that the hyaluronic acid is in the concentration range of 0.1 mg/ml to 20 mg/ml.
4. A hydrogel formulation according to claim 3, characterized in that it comprises collagen selected from at least one of a group comprising type 1-2-3 -4 collagen and hydrolyzed collagen, including animal origin, plant origin, recombinant human collagen, or mixtures thereof.
5. A hydrogel formulation according to claim 4, characterized in that the collagen is in the concentration range of 0.0001 mg/ml to 2 mg/ml.
6. A hydrogel formulation according to claim 1, characterized in that it additionally comprises sulfated glycosaminoglycan (sGAG).
7. A hydrogel formulation according to claim 6, characterized in that it comprises sulfated glycosaminoglycan selected from at least one of the group comprising chondroitin sulfate (CS), dermatan sulfate (DS), heparan sulfate (HS), heparin (Hep) or mixtures thereof.
8. A hydrogel formulation according to claim 7, characterized in that the sulfated glycosaminoglycan is in the concentration range of 0.005 mg/ml to 5 mg/ml.
9. A hydrogel formulation according to claim 1, characterized in that it additionally contains ascorbic acid and/or its derivatives.
10. A hydrogel formulation according to claim 9, characterized in that it comprises ascorbic acid derivatives selected from at least one of a group comprising L-ascorbic acid, tetrahexyldecyl ascorbate, ascorbyl glucoside, ethylated ascorbic acid, ascorbyl palmitate, magnesium ascorbyl palmitate, magnesium ascorbyl phosphate, calcium ascorbate, sodium ascorbate and sodium ascorbyl phosphate or mixtures thereof.
11. A hydrogel formulation according to claim 10, characterized in that the ascorbic acid derivative is in the concentration range of 0.002 mg/ml to 2 mg/ml.
12. A hydrogel formulation according to any one of the preceding claims, characterized in that the pH value of the formulation is in the range of 7.0 to 7.4, preferably in the range of 7.1 to 7.3.
13. A hydrogel formulation according to any one of the preceding claims, characterized in that the density of the formulation is in the range of 1,000 to 1,008 g/cm3.
14. A hydrogel formulation according to any one of the preceding claims, characterized in that the refractive index of the formulation is in the range of 1.3345 to 1.3348.
15. A hydrogel formulation according to any one of the preceding claims, characterized in that the viscosity (cP) of the formulation is in the range of 300 to 2000.
16. A hydrogel formulation according to any one of the preceding claims, characterized in that it additionally comprises linear forms of hyaluronic acid and/or collagen.
17. A hydrogel formulation according to any one of the preceding claims comprising the following production method:
- Producing hyaluronic acid-collagen hybrid cross-linked gels
- Adding non-crosslinked hyaluronic acid
- Adding sulfated GAG - Adding vitamin C
- Mixing for 5-50 hours at a mixing speed of 10-250 rpm
- Vacuum degassing of the mixture,
- Filling the mixture into syringes
- Performing vapor sterilization process
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR202118218 | 2021-11-22 | ||
| PCT/TR2022/051336 WO2023091120A2 (en) | 2021-11-22 | 2022-11-22 | A hydrogel formulation used as vitreous substitute and production method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4436620A2 true EP4436620A2 (en) | 2024-10-02 |
Family
ID=92632588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22896250.2A Pending EP4436620A2 (en) | 2021-11-22 | 2022-11-22 | A hydrogel formulation used as vitreous substitute and production method thereof |
Country Status (1)
| Country | Link |
|---|---|
| EP (1) | EP4436620A2 (en) |
-
2022
- 2022-11-22 EP EP22896250.2A patent/EP4436620A2/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2349168C (en) | Hyaluronic acid gel, method of its production and medical material containing it | |
| US7014860B1 (en) | Hyaluronic acid gel, process for producing the same, and medical material containing the same | |
| Soman et al. | Artificial vitreous replacements | |
| US5792103A (en) | Viscosurgical method and apparatus | |
| US5103840A (en) | Viscoelastic collagen gel for ophthalmic surgery | |
| JP2022533772A (en) | Chitosan and its uses | |
| Wang et al. | In-situ forming PEG-engineering hydrogels with anti-fouling characteristics as an artificial vitreous body | |
| JP2023550573A (en) | Chitosan-based beads, preparation, composition and applications | |
| US20060110459A1 (en) | Triple natural polymer viscoelastic composition | |
| AU2002350186B2 (en) | Combinations of viscoelastics for use during surgery | |
| ES2871020T3 (en) | Chitosan with anionic charge | |
| ES2537933T3 (en) | Viscoelastic gels in ophthalmic surgery | |
| EP4436620A2 (en) | A hydrogel formulation used as vitreous substitute and production method thereof | |
| WO2023091120A2 (en) | A hydrogel formulation used as vitreous substitute and production method thereof | |
| US20210220515A1 (en) | Viscoelastic agent material | |
| TR2021018218A1 (en) | A HYDROGEL FORMULATION AND PRODUCTION METHOD USED AS A VITREOUS SUBSTITUTE | |
| US20240189208A1 (en) | Biocompatible Product Having A Matrix Comprising a Polysaccharide Co-Crosslinked With Chitosan | |
| JP5461468B2 (en) | Method for producing hyaluronic acid gel and medical material containing the same | |
| EP4452225A1 (en) | Novel biocompatible substitutes of the vitreous humor | |
| Thacker et al. | Substitutes and Colloidal System for Vitreous Replacement and Drug Delivery: Recent Progress and Future Prospective. Polymers 2021, 13, 121 | |
| Baino et al. | Biofunctional Polymers: Vitreoretinal Surgery | |
| Garg | Dynamics of Ocular Surgical Adjuncts in Cataract Surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20240620 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |